Compare ASUR & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASUR | TTRX |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.9M | 298.8M |
| IPO Year | 1996 | 2025 |
| Metric | ASUR | TTRX |
|---|---|---|
| Price | $7.42 | $11.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | $13.11 | ★ $25.00 |
| AVG Volume (30 Days) | 90.2K | ★ 145.0K |
| Earning Date | 10-29-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $88,952,000.00 | N/A |
| Revenue This Year | $14.25 | N/A |
| Revenue Next Year | $8.65 | $900.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 63.39 | N/A |
| 52 Week Low | $6.80 | $2.57 |
| 52 Week High | $10.20 | $16.45 |
| Indicator | ASUR | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.82 | 42.42 |
| Support Level | $7.36 | $9.02 |
| Resistance Level | $7.98 | $14.39 |
| Average True Range (ATR) | 0.26 | 1.25 |
| MACD | -0.03 | -0.41 |
| Stochastic Oscillator | 30.69 | 1.09 |
Asure Software Inc is a provider of cloud-based Human Capital Management (HCM) software solutions delivered as Software-as-a-Service (SaaS) to businesses of all sizes. It facilitates small and mid-sized businesses (SMBs) to develop their Human Capital to get to the next level, stay compliant, and allocate their time, money, and technology toward growth. The company's HCM suite, named AsureHCM, includes cloud-based Payroll and Tax, HR, a Time and Attendance software. Its HR services range from HR projects to outsourcing payroll to HR consulting services. The firm sells its products majorly in the United States.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.